Report from Orexo AB’s extraordinary general meeting, December 18 2024

Election of new member of the board of directors
The extraordinary general meeting in Orexo AB (publ) on December 18 2024 resolved, in accordance with the nomination committee’s proposal, that the number of board members shall be six with no deputy board members. Friedrich von Bohlen und Halbach was elected as a new board member.

Remuneration to the board of directors
The extraordinary general meeting also resolved, in accordance with the nomination committee’s proposal, that Friedrich von Bohlen und Halbach shall receive board remuneration, pro rata to his mandate period, in accordance with the resolution of the Annual General Meeting on 26 April 2024. Furthermore, it was resolved that Friedrich von Bohlen und Halbach shall receive the additional board fee for acquisition of shares in Orexo, also pro rata to his mandate period. The resolution of the Annual General Meeting on 26 April 2024 regarding board remuneration shall continue to apply in all other respects.

Complete proposals regarding the resolutions by the extraordinary general meeting in accordance with the above are available at Orexo’s website, www.orexo.com.

For more information:
Orexo AB (publ.)

About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs.
On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information on Orexo, visit www.orexo.com. Follow Orexo on X, LinkedIn, and YouTube.